Reuters logo
BRIEF-Ionis eligible to get nearly $800 mln in milestones from deal with Janssen
November 16, 2017 / 12:44 PM / a month ago

BRIEF-Ionis eligible to get nearly $800 mln in milestones from deal with Janssen

Nov 16 (Reuters) - Ionis Pharmaceuticals Inc-

* Ionis Pharmaceuticals licenses second orally delivered antisense drug to Janssen

* Ionis Pharmaceuticals - licensed second orally delivered generation 2.5 antisense drug to Janssen Biotech, Inc. for which Ionis earned $5 million​

* Ionis Pharmaceuticals -Janssen to now assume all global development, regulatory, commercialization responsibilities for IONIS-JBI2-2.5(RX )for GI diseases​

* Ionis Pharma- ‍under global collaboration deal with Janssen, co eligible to receive nearly $800 million in regulatory, sales milestone payments, others

* Ionis Pharma- ‍in addition, will receive tiered royalties that on average are double-digits on sales from any product that is successfully commercialized​

* Ionis Pharmaceuticals Inc - ‍IONIS-JBI1-2.5(RX), first collaboration target, was licensed to Janssen last year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below